Home » Newsletters » BioWorld Science

BioWorld Science

April 14, 2022

View Archived Issues

IRF4-transgenic zebrafish model develops aggressive lymphoma

AAV gene therapy shows safety and efficacy to target ON-bipolar cells in the LRIT3-CSNB canine model

New prefusion-stabilized variants of human metapneumovirus fusion protein elicit neutralizing Abs

Efficient one-pot method for synthesis of oxoaporphines with potential antitumor activity

Beta-catenin antagonist ST-316 abrogates the oncogenic activity of Wnt

bbT-369: next-generation autologous CAR-T cells for the treatment of lymphoma

Novel humanized mouse model can be used for preclinical evaluation of cancer immunotherapies

Jiangsu Nhwa Pharmaceutical, Suzhou Nhwa Pharmaceutical Research present SIGMAR antagonists

New TGF-beta receptor type-1 inhibitors identified at Sichuan Kelun-Biotech Biopharmaceutical

Niche Pharmaceuticals patents new anti-infective agents

MRGPRX4 modulators discovered at Escient Pharmaceuticals

Landos Biopharma identifies new NLR family member X1 ligands

NXP-800, orally available HSF1 pathway inhibitor with antitumor activity

HDAC6 inhibition prevents peripheral nerve injury-induced hypersensitivity

BAY-3375968: a new anti-CCR8 antibody for cancer immunotherapy

AACR 2022: With ADCs established, branching out to irregular conjugation

VantAI and Janssen establish protein degrader discovery collaboration

SPK-001 demonstrates neutralization activity in vitro against SARS-CoV-2 variants of concern

Artelo reports new preclinical data for GPCR agonist ART-27.13 for cancer-induced cachexia

Inhaled CYB-004 shows advantages over intravenous and inhaled DMT

Insilico Medicine nominates USP1 small-molecule inhibitor as preclinical candidate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 8, 2026.
New York University identifies new analogues of mannose-6-phosphate
BioWorld Science
New York University has discovered new analogues of mannose-6-phosphate reported to be potentially useful for the treatment of memory impairment,...
ASCO 2026: Chinese biopharma arrives at ASCO with pivotal wins
BioWorld
If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s...
Bial-Portela discovers new OX1 receptor antagonists
BioWorld Science
Bial-Portela & Ca SA has patented new orexin OX1 receptor antagonists potentially useful for the treatment of anxiety disorders, depression, eating disorders,...
Autobahn on the fast track with bipolar thyroid agonist
BioWorld
Achieving high marks in the phase II Amplify-BD trial for bipolar I and II depression, Autobahn Therapeutics Inc.’s elunetirom, a brain-penetrant central nervous...